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Objectives: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for
Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to
methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia
caused by MRSA are generally worse than those observed with methicillin-susceptible S. aureus bac-
teraemia, clinical characteristics and treatment results in the trial’s pre-speciﬁed subset of patients
with MRSA were analysed.
Methods: Clinical characteristics and outcomes of patients receiving daptomycin were compared with
those receiving vancomycin plus low-dose gentamicin. Success was deﬁned as clinical improvement
with clearance of bacteraemia among patients who completed adequate therapy, received no poten-
tially effective non-study antibiotics and had negative blood cultures 6 weeks after end of therapy.
Results: Twenty of the 45 (44.4%) daptomycin patients and 14 of the 43 (32.6%) vancomycin/gentamicin
patients were successfully treated (difference 11.9%; conﬁdence interval 28.3 to 32.1). Success rates
for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60%
versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided MRSA endocarditis.
Cure rates in patients with septic emboli and in patients who received pre-enrolment vancomycin were
similar between treatment groups. However, in both treatment groups, success rates were lower in the
elderly ( 75 years). Persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of
vancomycin/gentamicin patients; among these patients, MICs of  2 mg/L occurred in ﬁve daptomycin
and four vancomycin/gentamicin patients. The clinical course of several patients may have been inﬂu-
enced by lack of surgical intervention.
Conclusions: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacterae-
mia or right-sided endocarditis.
Keywords: MRSA, endovascular infections, bloodstream infections, combination therapy, clinical trial
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Staphylococcus aureus is the most common cause of infective
endocarditis in many regions of the world
1 and in the USA is
second only to coagulase-negative staphylococci in causing
bacteraemia.
2 Since it was ﬁrst described in 1961, methicillin-
resistant S. aureus (MRSA) has become a common healthcare-
associated pathogen, causing one-third of the cases of S. aureus
endocarditis in the USA.
1 In recent years, a particularly virulent
clone of community-associated MRSA has been associated with
signiﬁcant disease in non-healthcare-associated settings,
3,4 and
it has found its way into hospitals as a cause of healthcare-
associated bacteraemias.
5–7
Numerous studies have compared the characteristics of
methicillin-susceptible S. aureus (MSSA) and MRSA bacteraemia
and endocarditis. Fowler et al.
8 found that patients with MRSA
endocarditis were more likely to have underlying diabetes melli-
tus, an immunocompromised state, recent invasive procedure,
presumed intravenous (iv) source, healthcare-associated disease
and persistent bacteraemia. For reasons that may relate to the
bacterial strain, the patient population or the antimicrobials used
for therapy, the duration of bacteraemia in MRSA bloodstream
infections and endocarditis is, on average, longer than that
associated with MSSA.
1,8,9
While the morbidity and mortality associated with both
MSSA and MRSA bacteraemia and endocarditis are notable, the
rates of complicated disease and death among individuals
infected with MRSA are higher, even after controlling for the
increased numbers of co-morbidities in the MRSA group.
10,11
This phenomenon was also observed among patients participat-
ing in the recent randomized trial of daptomycin versus standard
therapy for these conditions.
8 Whether lower treatment success
rates are due to the microorganism or the antimicrobials used to
treat the infection remains unknown. The suboptimal treatment
results observed when vancomycin rather than semi-synthetic
penicillin is used to treat MSSA bacteraemia and endocarditis
12–15
leads to speculation with regard to the potency of vancomycin
and its potential impact on the outcomes of treatment of serious
MRSA infections. The availability of other antimicrobial agents
with activity against MRSA provides an opportunity to examine
alternative regimens. The aim of the study was to compare the
clinical characteristics and outcomes of patients with MRSA bac-
teraemia or endocarditis treated with daptomycin with those of
patients treated with vancomycin and short-course gentamicin.
Methods
Design overview
Patients participated in this open-label, multicentre, international,
randomized trial between August 2002 and March 2005. The trial is
registered on ClinicalTrials.gov (NCT00093067). The parent study
was a non-inferiority trial to assess the efﬁcacy and safety of dapto-
mycin compared with standard therapy (either an antistaphylococcal
penicillin or vancomycin, with initial short-course gentamicin) for
MSSA and MRSA bacteraemia and endocarditis.
8 Patients were ran-
domized by a computerized central randomization schedule to either
daptomycin or standard therapy in a 1:1 ratio. The primary outcome
was the clinical success rate at the test of cure visit 42 days after
completion of therapy. The null hypothesis was that the treatments
differed by at least 20%. The central database of this trial was used
to perform a detailed analysis of the pre-speciﬁed subset of patients
with MRSA bacteraemia or endocarditis.
Setting and participants
The protocol, approved by the Institutional Review Board at each
site, was consistent with the principles of the Declaration of
Helsinki. To improve comparability among patients and to accom-
modate the guidelines for a registrational trial, some patients were
excluded from randomization into the trial. Eligible patients were
 18 years of age with one or more blood cultures growing S. aureus
within 2 calendar days prior to randomization. Patients whose crea-
tinine clearance was ,30 mL/min and those with known osteomyel-
itis, polymicrobial bacteraemia or pneumonia were ineligible for
participation. Prior receipt of an antibiotic active against S. aureus
was not an exclusion criterion. Patients with prosthetic valves were
ineligible to participate, as were those who had intravascular foreign
material at the time a positive blood culture was drawn (unless the
investigator intended to have the material removed within 4 days
after the ﬁrst dose of study medication). All patients or their author-
ized representatives provided written informed consent.
Interventions: MRSA subset
Participants with MRSA bacteraemia or endocarditis were to receive
either daptomycin 6 mg/kg iv every 24 h or standard therapy (van-
comycin 1 g iv every 12 h with gentamicin 1 mg/kg iv every 8 h for
the ﬁrst 4 days of treatment).
16 Vancomycin and gentamicin doses
were adjusted by investigators. Blood cultures were performed daily
until they were negative, at the end of therapy and 42 days after
completion of therapy (test of cure). Haematological parameters,
coagulation tests, creatine phosphokinase levels and chemistry pro-
ﬁles were monitored during therapy and at the test of cure visit.
Deﬁnitions and outcomes
The investigators established an initial diagnosis based on the modi-
ﬁed Duke criteria
17 and determined the duration of therapy accord-
ing to their working diagnosis. Complicated bacteraemia was
present when MRSA was isolated from the blood on at least 2 days
during the ﬁrst 5 days of therapy, metastatic infection was found or
the infection involved prostheses that were not removed within 4
days. These patients, who did not have endocarditis as deﬁned by
the Duke criteria, were to receive a minimum of 28 days of therapy.
Uncomplicated bacteraemia was usually treated for 10–14 days. If
patients had deﬁnite or possible endocarditis
17 in the absence of pre-
disposing abnormalities or active lesions of the aortic or mitral
valves, the diagnosis of right-sided endocarditis was established.
Left-sided endocarditis was deﬁned as described in the modiﬁed
Duke criteria.
17 The planned treatment course for patients with
endocarditis was a minimum of 28 days.
The ﬁnal diagnoses and outcomes were determined by an indepen-
dent adjudication committee blinded to treatment.
8 Conﬂicts of opinion
between members of the committee were settled by discussion leading
to consensus. Persisting or relapsing bacteraemia was investigator-
deﬁned, meaning that the investigator decided when to discontinue
study medication in the case of ongoing or recurrent MRSA bac-
teraemia. The independent adjudication committee reviewed the role of
persisting or relapsing MRSA bacteraemia in its analysis of outcomes.
The treatment outcome was categorized as success if an ade-
quately treated patient was clinically cured or improved and blood
cultures were negative 42 days after completion of therapy. The
outcome was categorized as failure if a patient experienced
Rehm et al.
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any reason. Failure was also deﬁned by premature discontinuation of
therapy because of a treatment-limiting adverse event, receipt of
potentially effective non-study antibiotics or lack of blood culture at
the 42 day post-therapy evaluation.
Statistical analysis
Differences between the patients in the treatment groups were ana-
lysed using Fisher’s exact test for categorical data (occurrence of
adverse events and laboratory abnormalities) and analysis of covari-
ance for continuous data (change from baseline serum creatinine).
The 95% conﬁdence interval (CI) for the difference in success rates
(daptomycin minus vancomycin/gentamicin) was calculated based
on the normal approximation to the binomial distribution. Survival
curves were estimated using the Kaplan–Meier methodology, and
the treatment groups were compared using the Wilcoxon and
log-rank tests. All analyses were performed using SAS
w software,
Version 9.1 (SAS Institute, Inc., Cary, NC, USA).
Results
Among the 89 patients with MRSA bacteraemia or endocarditis,
45 received daptomycin, 43 were given vancomycin/gentamicin
and 1 was inadvertently treated with a semi-synthetic penicillin.
The latter patient was excluded from further data analyses.
Table 1 summarizes the baseline demographic information
for the MRSA patients. The treatment groups were well balanced
with regard to clinical characteristics. Twice as many patients
who received daptomycin were 75 years of age and older (22%
versus 9%), but this difference was not statistically signiﬁcant.
Underlying medical conditions were also similar between the
treatment groups (Table 1). More than one-third of the patients
had diabetes mellitus, and injection drug use was present in
one-quarter of the patients. The systemic inﬂammatory response
syndrome was observed among three-quarters of the patients in
both groups. Four patients who received daptomycin and ﬁve
who received vancomycin/gentamicin had septic pulmonary
emboli at baseline (9% and 11%, respectively).
The ﬁnal diagnoses, as established by the adjudication com-
mittee, are summarized in Table 1. Half of the patients in each
group had complicated MRSA bacteraemia without documented
endocarditis, and approximately one-quarter were diagnosed
with uncomplicated bacteraemia. In the daptomycin arm, eight
patients had right-sided and ﬁve had left-sided endocarditis,
compared with six with right-sided and four with left-sided
endocarditis in the vancomycin/gentamicin arm.
The mean and median trough vancomycin levels were 14.9
and 14.7 mg/L, respectively. Thirty-nine of the 43 patients
(91%) in the vancomycin/gentamicin arm received a mean of
4.3 days of initial gentamicin therapy as part of the study
protocol.
Table 1. Demographics, baseline characteristics and ﬁnal diagnosis of MRSA patients
Daptomycin (n ¼ 45) Vancomycin/gentamicin (n ¼ 43)
Age (years), median (range) 57 (22–86) 54 (25–91)
Gender (male), n (%) 23 (51) 25 (58)
Race, n (%)
black 10 (22) 9 (21)
Caucasian 31 (69) 29 (67)
Hispanic 3 (7) 2 (5)
other 1 (2) 3 (7)
Weight (kg), median (range) 70.5 (52.0–119.4) 71.5 (49.9–119.9)
BMI (kg/m
2), median (range) 26.5 (18.6–49.6) 25.4 (18.9–44.0)
Creatinine clearance (mL/min), median (range) 77.6 (29.4–200.8) 76.3 (17.9–171.0)
Underlying conditions, n (%)
injection drug use 12 (27) 11 (26)
diabetes mellitus 17 (38) 18 (42)
septic pulmonary emboli 4 (9) 5 (12)
HIV infection 2 (4) 0
history of endocarditis 3 (7) 3 (7)
underlying valvular heart disease 9 (20) 6 (14)
presence of foreign material
intravascular 5 (11) 9 (21)
extravascular 14 (31) 14 (33)
SIRS 35 (78) 33 (77)
Final diagnosis, n (%)
a
uncomplicated bacteraemia 10 (22) 11 (26)
complicated bacteraemia 22 (49) 22 (51)
right-sided endocarditis 8 (18) 6 (14)
left-sided endocarditis 5 (11) 4 (9)
BMI, body mass index; HIV, human immunodeﬁciency virus; SIRS, systemic inﬂammatory response syndrome.
aAs determined by the adjudication committee.
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1415Six weeks following the conclusion of therapy, the overall
success rate was 44.4% for patients who received daptomycin
and 32.6% for patients in the vancomycin/gentamicin arm
(difference in rates 11.9%; CI 28.3 to 32.1) (Table 2). The
success rates in the treatment of complicated bacteraemia were
45% in the daptomycin group and 27% in the vancomycin/
gentamicin group. For patients with uncomplicated bacteraemia,
success rates were 60% for daptomycin and 45% for vancomy-
cin/gentamicin. Four of eight patients receiving daptomycin and
three of six receiving vancomycin/gentamicin were successfully
treated for right-sided endocarditis. Of those with septic pulmon-
ary emboli, three of the four daptomycin-treated patients and
three of the ﬁve vancomycin/gentamicin-treated patients were
considered cures. None of the nine patients with left-sided endo-
carditis was successfully treated.
Success rates were somewhat lower among older patients.
Among patients younger than 75 years of age, 18 of 35 (51.4%)
in the daptomycin arm and 14 of 39 (35.8%) in the vancomycin/
gentamicin group were judged to have had a successful outcome,
but among patients 75 years of age or older, 2 of the 10 receiving
daptomycin and none of the 4 in the vancomycin/gentamicin arm
were successfully treated. The two patients in the older age group
who were treated successfully with daptomycin had complicated
bacteraemia; the remainder who received daptomycin were diag-
nosed with uncomplicated bacteraemia (one patient), complicated
bacteraemia (four patients) and left-sided endocarditis (three
patients). The diagnoses for patients 75 years of age and older
who received vancomycin/gentamicin were complicated bacterae-
mia (three patients) and right-sided endocarditis (one patient).
Fourteen patients had intravascular material in place at the
time of randomization. Ten of the 14 had pacemakers, deﬁbrilla-
tors or tunnelled catheters, and 4 of these 10 devices were
removed. Overall, two of ﬁve daptomycin-treated patients and
three of the nine who received vancomycin/gentamicin were
treated successfully.
The overall death rate among patients in the daptomycin
group was 12/45 (27%), compared with 8/43 (19%) for the
vancomycin/gentamicin group (P ¼ 0.45). A Kaplan–Meier plot
(Figure 1) demonstrates no signiﬁcant differences in survival
through day 150 (Wilcoxon P ¼ 0.25, log-rank P ¼ 0.42).
Among patients with persistent or relapsing MRSA bacteraemia,
7 of the 12 receiving daptomycin (58%) and 6 of 9 (67%) in the
vancomycin/gentamicin group died (Table 3).
Because of recent in vitro studies suggesting that exposure of
S. aureus to vancomycin may reduce susceptibility to daptomy-
cin
18 and reports of trends toward rising vancomycin MICs,
19
we reviewed pre-treatment and baseline MICs. Daptomycin
isolates with MICs  1 mg/L were considered susceptible; the
susceptibility cut-off for vancomycin MICs was  2 mg/L.
20
Thirty-six of the 45 patients (80%) who received daptomycin
and 29 of the 43 (67%) patients taking vancomycin/gentamicin
had received vancomycin for 1–22 days (mean and median, 3
days) within 30 days prior to study entry. Five patients in the
daptomycin arm and four in the vancomycin arm received  5
days of vancomycin prior to study entry. In the daptomycin
group, the baseline MIC for daptomycin was 0.25 mg/L for
35/45 (78%) patients and 0.5 mg/L for the remaining 10
patients. The baseline vancomycin MICs were 0.5 mg/L for 22
of 43 patients (51%) and 1 mg/L for 21 of 43 patients (49%).
There was no evidence of any impact of prior vancomycin treat-
ment on baseline MICs. Likewise, there was no evidence of
reduced success rates with vancomycin pre-treatment (Figure 2).
Twelve of the 45 (27%) daptomycin patients and 9 of the 43
(21%) vancomycin/gentamicin patients experienced persisting or
relapsing MRSA bacteraemia (Table 3). Several of these patients
were immunocompromised; many had deep-seated foci of infec-
tion that might have beneﬁted from surgical intervention but
they were deemed poor surgical candidates due to their overall
condition. There was no correlation between receipt of vanco-
mycin prior to study entry and subsequent development of per-
sisting or relapsing MRSA bacteraemia. Eight of the 12 patients
(67%) in the daptomycin group who failed therapy related to
persistence or relapse had prior vancomycin therapy, compared
with a rate of prior vancomycin exposure of 28/33 (85%) among
daptomycin patients who did not (P ¼ 0.22). Similarly, for
those randomized to receive vancomycin/gentamicin, 4/9 (44%)
of the patients who did and 25/34 (74%) of those who did not
experience persisting or relapsing MRSA bacteraemia had
previous vancomycin therapy (P ¼ 0.12). Among patients who
failed therapy because of persistence or relapse of bacteraemia,
Table 2. Treatment success rates for MRSA
Bacteraemia
a Endocarditis
a
Total
a,b uncomplicated complicated right-sided left-sided
Daptomycin 6/10 (60%) 10/22 (45%) 4/8 (50%) 0/5 (0%) 20/45 (44.4%)
Vancomycin/gentamicin 5/11 (45%) 6/22 (27%) 3/6 (50%) 0/4 (0%) 14/43 (32.6%)
aSuccess/number treated.
bDifference in success rates¼11.9% (CI 28.3 to 32.1).
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Figure 1. The Kaplan–Meier plot of overall survival. Wilcoxon P ¼ 0.25,
log-rank P ¼ 0.42.
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1416isolates from 5 of the 12 in the daptomycin arm had an MIC
increase to 2 mg/L in cultures drawn a median of 7 (mean 17)
days after study initiation. Likewise, isolates from four of the
nine patients in the vancomycin/gentamicin arm had an MIC
increase to 2 mg/L at the local or central laboratory, found a
median of 16 (mean 27) days after randomization. The differ-
ence in time to documentation of isolates with increased MICs
was inﬂuenced by variations in frequency of sampling and the
fact that two isolates from the daptomycin group were from
patients with left-sided endocarditis who were not surgical can-
didates and experienced early failure of therapy.
Among investigator-reported adverse events, the rates of
nausea and anaemia were signiﬁcantly higher (P ¼ 0.03 and 0.05,
respectively; Fisher’s exact test) in vancomycin/gentamicin-
treated patients. With regard to laboratory abnormalities, serum
Table 3. Patients with persisting/relapsing MRSA infection
Diagnosis
Days of
therapy Complications/interventions Ultimate outcome
Daptomycin
cBAC 3 pacemaker, prosthetic hip; pacemaker not removed care withdrawn, died
3 chronic osteomyelitis of humerus, prosthesis in situ; no surgery died
4 cardiogenic shock, aortic balloon pump; central venous catheter infection,
possible septic thrombophlebitis; catheter not removed
died
9 undiagnosed mycotic aneurysm of thoracic aorta, progression of myeloma; no
surgery
died
13 psoas abscess, vertebral osteomyelitis; abscess drained 3 days after course of
study medication completed
died
14 infected subcutaneous intravenous port, possible septic thrombophlebitis; port
removed day 2, pocket inadequately debrided
cured with additional antibiotics
23 septic arthritis; knee aspirated day 2, synovectomy day 5 and again 20 days
after end of study medication when relapse diagnosed
cured with additional antibiotics
35 pancreas transplant, unrecognized retroperitoneal abscess; abscess diagnosed
day 31, drainage attempted day 32
cured with additional antibiotics
LIE 6 prosthetic aortic IE, sternal osteomyelitis; re-do aortic valve replacement,
sternal debridement 2 days after end of study medication
cured with additional antibiotics
7 mitral/aortic IE, pulmonary oedema; no surgery made DNR, died
8 mitral IE, stroke; no surgery died
14 infected lumbar spine prosthesis, aortic valve endocarditis; L2-3 debridement,
hardware removed 11 days after end of study medication
cured with additional antibiotics
Vancomycin/gentamicin
cBAC 3 decubitus ulcers, renal failure, sepsis; no debridement died
5 septic thrombophlebitis, osteomyelitis; no surgery cured with additional antibiotics
13 cutaneous T cell lymphoma, infected ulcers; no debridement died
15 high grade SAB, psoas and scrotal abscesses, MRSA pneumonia; inadequate
drainage of abscesses
cured with additional antibiotics
26 enterocutaneous ﬁstulae, inadequately drained subphrenic abscesses; septic
thrombophlebitis
cured with additional antibiotics
RIE 3 pacemaker IE, right atrial vegetation, sepsis, acute renal failure; pacemaker
not removed
died
7 pacemaker endocarditis; pacemaker not removed died
LIE 7 aortic IE, septic emboli (retina, spleen), septic shock; no surgery died
27 mitral IE, intramural abscess, stroke; no surgery care withdrawn, died
cBAC, complicated bacteraemia; DNR, do not resuscitate; IE, infective endocarditis; LIE, left-sided endocarditis; RIE, right-sided endocarditis; SAB,
S. aureus bacteraemia.
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1417creatinine levels trended higher among those in the vancomycin/
gentamicin arm. At days 21 and 28, there was a statistically
signiﬁcant difference between mean serum creatinine levels of
patients receiving vancomycin/gentamicin compared with those
receiving daptomycin (Figure 3). The higher incidence of creatine
phosphokinase elevations .500 U/L among daptomycin-treated
patients did not translate into more reports of musculoskeletal
adverse events (Table 4).
A total of 3 of the 45 patients in the daptomycin arm (7%)
failed therapy because of treatment-limiting adverse events (one
patient each with vomiting, diabetic gastroparesis and renal failure),
compared with 7 of the 43 patients in the vancomycin/gentamicin
arm (16%), in which renal dysfunction was the most common
reason for failure due to treatment-limiting adverse events.
Discussion
The treatment of bacteraemia and endocarditis caused by MRSA
continues to be challenging. Despite advances in diagnostic
techniques and supportive care, patients with bacteraemia may
develop suppurative complications and metastatic infections. In
particular, the development of infective endocarditis is feared.
Patients may become unstable so quickly that they become ineli-
gible for otherwise life-saving surgical therapy. For many years,
there have been no signiﬁcant advances related to antimicrobial
therapy for MRSA bacteraemia and endocarditis.
The current study, the only prospective and randomized trial
comparing a newly available antibiotic with standard therapy for
MRSA bacteraemia and endocarditis, provides a unique opportu-
nity to address questions about the role of antimicrobials in treating
these life-threatening infections. In this analysis of patients with
MRSA bacteraemia and endocarditis, daptomycin performed
as well as vancomycin/gentamicin, with fewer adverse events.
Even among older patients, a group at higher risk of morbidity
and mortality, daptomycin performed at least as well as standard
therapy. Success rates among patients with septic pulmonary
emboli were similar in both treatment arms. This result is con-
sistent with experimental models demonstrating the efﬁcacy of
daptomycin for haematogenous S. aureus infections of the lung.
21
Because stringent criteria were used to deﬁne outcomes, the
overall success rates in both treatment arms were low. Some of
the reasons for failure, such as lack of adherence to protocol or
discontinuation of therapy because of adverse events, were
related to the study format. Several patients who were considered
failures secondary to persisting or relapsing bacteraemia were
found to have deep-seated foci of infection, including osteo-
myelitis, infected devices and abscesses that were not apparent
at the time of study entry.
Prior vancomycin therapy did not appear to inﬂuence the
treatment response, a potentially signiﬁcant ﬁnding in view of in
vitro studies suggesting potential increases in daptomycin and
vancomycin MICs among S. aureus strains exposed to vancomy-
cin.
18,22,23 The lack of success of therapy for patients with left-
sided endocarditis in both treatment arms is of concern but difﬁ-
cult to interpret in light of the small number of patients with
endocarditis in this study. Several of these patients, as well as
others with right-sided endocarditis or complicated bacteraemia,
failed therapy because treating physicians determined that they
were not candidates for surgical intervention. The fact that most
of the patients in the vancomycin arm received concomitant
short-course gentamicin therapy may have inﬂuenced the rate of
nephrotoxicity in this group; an analysis is under review. Recent
guidelines state that the addition of gentamicin for therapy of
S. aureus native valve endocarditis is optional.
16
The reasons that MRSA bacteraemia and endocarditis are so
difﬁcult to treat are multifaceted. They are related to the patient
populations who develop infections, characteristics of MRSA
and the traits of the antibiotics used to treat MRSA.
Host factors certainly impact outcomes
10 and there has been
a change in the types of patients developing S. aureus
bacteraemia and endocarditis: chronic illness and exposure to
healthcare interventions are now more common risk factors than
injection drug use.
1 Co-morbid conditions such as age, diabetes
mellitus, chronic indwelling central catheters and paravalvular
complications have been shown to predict mortality, particularly
among patients with left-sided endocarditis.
24–26
0.5
0 7 14 21 28
0.7
0.9
1.1
1.3
1.5
1.7
1.9
Study day
C
r
e
a
t
i
n
i
n
e
 
(
m
g
/
d
L
)
* * Vancomycin/gentamicin
Daptomycin
Figure 3. Mean serum creatinine. *P   0.05 compared with daptomycin for
change from baseline. Bars represent the standard error of the means.
Table 4. Muscle effects
Daptomycin (n ¼ 45) n (%) Vancomycin/gentamicin (n ¼ 43) n (%) P value
a
Reported clinical adverse events
CPK increased 2 (4) 0 0.49
musculoskeletal events 11 (24) 20 (47) 0.04
discontinued therapy due to CPK 1 (2) 0 .0.99
Lab abnormalities
CPK shift from normal to .500 IU/L 4/38 (11) 0/36 0.12
CPK, creatine phosphokinase.
aFisher’s exact test.
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biotics illustrates the role of organism-speciﬁc traits in response to
therapy. There are difﬁculties in deﬁning antibiotic susceptibility
and resistance,
27 but there has been a general rise in vancomycin
MICs among S. aureus,
19 with an associated increased failure rate
of vancomycin in treating S. aureus bacteraemia when the vanco-
mycin MIC is in the upper end of the ‘susceptible’ range.
28–33
Most clinical microbiology laboratories do not screen MRSA iso-
lates for vancomycin heteroresistance, which is not detected with
automated susceptibility testing.
34 Importantly, in the current
study, the baseline MIC testing of the isolates showed that they
were uniformly susceptible to daptomycin (0.25–0.5 mg/L) and
vancomycin (0.5–1 mg/L). The MICs for strains that are initially
susceptible may rise during therapy; for daptomycin, increases in
MICs appear to involve genetic changes at several sites.
35
Finally, factors associated with the antimicrobials used to treat
MRSA bacteraemia and endocarditis have been examined in an
effort to explain the excessive mortality observed in these con-
ditions.
9,12,36 Since the bactericidal activity of vancomycin is
time-dependent, some have suggested that higher trough levels
(i.e. in the range of 15–20 mg/L or higher) might be useful,
37 but
recent reports demonstrated increased toxicity without improve-
ment in outcome when high-dose vancomycin was used to treat
MRSA infections.
29,38 Vancomycin tolerance has been associated
with poor outcomes.
14,39,40 Among patients with left-sided native
valve endocarditis due to S. aureus, timely surgical intervention
may be at least as important as antimicrobial therapy.
24,26
There are several potential limitations to this report, including
the fact that it represents a pre-speciﬁed subset analysis rather
than a prospective, blinded study. Patients with renal failure and
those with prosthetic devices or long-term indwelling venous cath-
eters that could not be removed were to be excluded. During the
course of therapy, foci of infection such as abscess, osteomyelitis
and indwelling devices became apparent in several cases; the type
and timing of surgical intervention that might have impacted out-
comes was not standardized. Persisting and relapsing bacteraemia
was investigator-deﬁned, and we were unable to make a statement
with regard to the mean duration of bacteraemia because of the
limitations in collecting daily blood cultures. The number of
patients with left-sided endocarditis due to MRSA was small, and
there were no treatment successes in this group. In this study, the
daptomycin MICs for baseline and subsequent isolates were con-
ﬁrmed at a central laboratory, but the vancomycin MICs for sub-
sequent isolates were usually determined by local laboratories.
Conclusions
Cases of bacteraemia and endocarditis due to MRSA continue to
be associated with high rates of morbidity and mortality. The
reasons are multifactorial, including underlying patient conditions,
characteristics of S. aureus itself and issues related to vancomy-
cin, the historical gold standard for treatment of serious MRSA
infections. Daptomycin appears to be a therapeutic option for
patients with MRSA bacteraemia and right-sided endocarditis.
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